Diurnal glycemic patterns during an 8-week open-label proof-of-concept trial of empagliflozin in type 1 diabetes

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Perkins, Bruce A ^a,d   Cherney, David Z I ^b   Soleymanlou, Nima ^c   Lee, Justin A ^a   Partridge, Helen ^a   Tschirhart, Holly ^a   Zinman, Bernard ^a,d   Mazze, Roger ^e   Fagan, Nora ^f   Kaspers, Stefan ^g   Woerle, Hans Juergen ^g   Broedl, Uli C ^g   Johansen, Odd Erik ^h  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e WHO Collaborating Ctr Ref Res S   (United States)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h Boehringer Ingelheim Norway KS   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; HEMOGLOBIN A1C; PLACEBO; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; MALE; OPEN STUDY; SENSITIVITY ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 1; GLUCOSE BLOOD LEVEL; METABOLISM; PHYSIOLOGY; PILOT STUDY; YOUNG ADULT;

ADULT; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PILOT PROJECTS; YOUNG ADULT;

EID: 84952682963     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141085     Document Type: Article

References (29)

1. Imran SA, Rabasa-Lhoret R, Ross S, Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Targets for glycemic control. Can J Diabetes. 2013; 37 Suppl 1:S31-4.
2. Wood J, Miller K, Maahs D, Beck R, Dimeglio L, Libman I, et al. T1D Exchange clinic network. Most youth with type 1 diabetes in the T1D exchange clinic registry do not meet American Diabetes Association or Internation Society for Pediatric and Adolescent Diabetes Clinical Guidelines. Diabetes Care. 2013; 36:2035-7. doi: 10.2337/dc12-1959 PMID: 23340893
3. Gerstl EM, Rabl W, Resenbauer J, Grobe H, Hofer SE, Krause U, et al. Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27,035 patients from 207 centers in Germany and Austria during the last decade. Eur J Pediatr. 2008; 167(4):447-53. PMID: 17924142
4. The Diabetes Control and Compications Research Group. Weight gain associated with intensive therapy in the diabetes control and complication trial. Diabetes Care. 1988; 11(7):567-73. PMID: 2904881
5. The Diabetes Control and Compications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. PMID: 8366922
6. Cuypers J, Mathieu C, Benhalima K. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice. Acta Clin Belg. 2013; 68(4):287-93. doi: 10.2143/ACB.3349 PMID: 24455799.
7. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012; 44(4):375-93. doi: 10.3109/07853890.2011.560181 PMID: 21495788.
8. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacology & therapeutics. 2013; 139 (1):51-9. doi: 10.1016/j.pharmthera.2013.04.003 PMID: 23563279.
9. Cherney DZ, Perkins BA. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection? Can J Diabetes. 2014; 38(5):356-63. Epub 2014/09/07. doi: 10.1016/j.jcjd.2014.05.006 PMID: 25192954.
10. Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014; 37(5):1480-3. doi: 10.2337/dc13-2338 PMID: 24595630.
11. Luippold G, Klein T, Mark M, Grempler R. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes, obesity & metabolism. 2012; 14(7):601-7. doi: 10.1111/j.1463-1326.2012.01569.x PMID: 22268612.
12. Mudallar S, Armstrong D, Mavian A, O'Connor-Semmes R, Mydlow P, Ye J, et al. Remogliflozin etabonate, a selective inhibitor of sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care. 2012; 35:2198-200. doi: 10.2337/dc12-0508 PMID: 23011728
13. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes, obesity & metabolism. 2012; 14(1):5-14. doi: 10.1111/j.1463-1326.2011.01511.x PMID: 21955459.
14. Brand T, Macha S, Mattheus M, Pinnetti S, Woerle HJ. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther. 2012; 29(10):889-99. doi: 10.1007/s12325-012-0055-3 PMID: 23054692.
15. Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015; 38(3):412-9. Epub 2014/10/02. doi: 10.2337/dc13-2955 PMID: 25271207.
16. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014; 129(5):587-97. Epub 2013/12/18. doi: 10.1161/CIRCULATIONAHA.113.005081 PMID: 24334175.
17. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovascular diabetology. 2014; 13:28. Epub 2014/01/31. doi: 10.1186/1475-2840-13-28 PMID: 24475922; PubMed Central PMCID: PMC3915232.
18. Mazze RS, Strock E, Wesley D, Borgman S, Morgan B, Bergenstal R, et al. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes technology & therapeutics. 2008; 10(3):149-59. Epub 2008/05/14. doi: 10.1089/dia.2007.0293 PMID: 18473688.
19. Skrtic M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014; 57(12):2599-602. Epub 2014/10/05. doi: 10.1007/s00125-014-3396-4 PMID: 25280671.
20. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes, obesity & metabolism. 2013; 15(7):613-21. Epub 2013/01/30. doi: 10.1111/dom.12073 PMID: 23356556.
21. Mazze R. The future of self-monitored blood glucose: Mean blood glucose versus glycosylated hemoglobin. Diabetes technology & therapeutics. 2008; 10:S93-S101.
22. Bergenstal RM, Ahmann AJ, Bailey T, Beck RW, Bissen J, Buckingham B, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes technology & therapeutics. 2013; 15(3):198-211. doi: 10.1089/dia.2013.0051 PMID: 23448694.
23. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012; 35(6):1232-8. doi: 10.2337/dc11-1926 PMID: 22492586
24. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA (1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012; 35(7):1473-8. doi: 10.2337/dc11-1693 PMID: 22446170; PubMed Central PMCID: PMC3379599.
25. Wilding JP, Ferrannini E, Fonseca VA, WilpshaarW, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes, obesity & metabolism. 2013; 15(5):403-9. doi: 10.1111/dom.12038 PMID: 23163880.
26. Nauck M, Del Prato S, Meier J, Duran-Garcia S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011; 34(9):2015-22. doi: 10.2337/dc11-0606 PMID: 21816980
27. Henry R, Murray A, Marmolejo M, Hennicken D, Ptaszynska A, List J. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. International Journal of Clinical Practice. 2012; 66:446-56. doi: 10.1111/j.1742-1241.2012.02911.x PMID: 22413962
28. Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009; 32(9):1656-62. doi: 10.2337/dc09-0517 PMID: 19528367; PubMed Central PMCID: PMC2732143.
29. Polidori D, Sha S, Mudaliar S, Ciaraldi T, Ghosh A, Vaccaro N, et al. Canagliflozin lower postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013; 36(8):2154-61. doi: 10.2337/dc12-2391 PMID: 23412078